SCHEMBL7300968

SCHEMBL7300968

O=C1Nc2ccc(Cc3ccccc3)c3cccc1c23

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 1/20 0.50
CDK5R1 Q15078 1/20 0.50
POLB P06746 5/20 0.49
TYMS P04818 1/20 0.48
ALPL P05186 1/20 0.47
KDM4E B2RXH2 9/20 0.47
ALDH1A1 P00352 8/20 0.47
HPGD P15428 6/20 0.47
HSD17B10 Q99714 6/20 0.47
CASP1 P29466 4/20 0.47
CASP7 P55210 4/20 0.47
HTT P42858 1/20 0.47
RORC P51449 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GAA P10253 2/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
ESR1 P03372 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22532759 0.87 CDK5 (0.47) CDK5CDK5R1POLBTYMSALPL
SCHEMBL22532698 0.86 KDM4E (0.46) CDK5CDK5R1POLBTYMSALPL
SCHEMBL29774577 0.84 TYMS (0.60) CDK5CDK5R1POLBTYMSALPL
SCHEMBL22533020 0.83 MEN1 (0.44) CDK5CDK5R1POLBTYMSALPL
SCHEMBL29774557 0.82 PARP1 (0.43) CDK5CDK5R1POLBTYMSALPL
SCHEMBL22532871 0.82 DRD4 (0.47) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL29774551 0.82 DRD4 (0.47) KDM4EALDH1A1HPGDHSD17B10CASP1
SCHEMBL14712322 0.81 KDM4E (0.58) CDK5CDK5R1POLBTYMSALPL
SCHEMBL22532842 0.81 CDK5 (0.44) CDK5CDK5R1POLBTYMSALPL
SCHEMBL29774617 0.81 PARP1 (0.51) KDM4EALDH1A1HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2023-03-16 US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 US disclosed
EP-3953332-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 Therapeutics, Inc. (US) 2022-02-16 EP disclosed
CN-113677664-A Tricyclic degradants of IKAROS and AIOLOS C4医药公司 2021-11-19 CN disclosed
WO-2020210630-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2020-10-15 WO disclosed
US-5081131-A Omega-((hetero)alkyl)benz(cd)-indol-2-amines AMERICAN CYANAMID COMPANY (US) 1992-01-14 US disclosed
EP-0230035-A2 Omega-[(hetero)alkyl]benz[cd]indol-2-amines AMERICAN CYANAMID COMPANY (US) 1987-07-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos CRBN, IKZF1, IKZF3 CDK5 1232/4885CDK5R1 1955/4885POLB 2335/4885
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS CRBN, IKZF1, IKZF3 CDK5 1232/4885CDK5R1 1955/4885POLB 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.